


**Supplementary Figure 1.** Activation of DDR pathway in the TNBC cell panel. DDR: DNA damage and response; TNBC: triple negative breast cancer



**Supplementary Figure 2.** Body weight measurements in MDA-231 (A) and MDA-468 (B) xenograft containing mice during treatment with prexasertib, erlotinib, and both prexasertib and erlotinib